Advanced glycation end-products (AGEs): Involvement in aging and in neurodegenerative diseases

Amino Acids

Volumn 35, Issue 1, 2008, Pages 29-36

  Grillo, M A ^a   Colombatto, S ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Amadorines; Detoxification; RAGE; TAGE

Indexed keywords

1,2 DICARBONYL DERIVATIVE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CARBOHYDRATE; GLUCOSE; GLYOXAL; GLYOXALASE; METHYLGLYOXAL;

AGING; AMADORI REARRANGEMENT; CHEMICAL REACTION; CHEMICAL STRUCTURE; DEGENERATIVE DISEASE; DETOXIFICATION; ENZYME ACTIVITY; HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; REVIEW;

AGING; ALDEHYDE OXIDOREDUCTASES; ANIMALS; GLYCOSYLATION END PRODUCTS, ADVANCED; GLYOXAL; HUMANS; PYRUVALDEHYDE; RECEPTORS, IMMUNOLOGIC;

EID: 44949216859     PISSN: 09394451     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00726-007-0606-0     Document Type: Review

References (44)

1. Ahmed N, Thornalley PJ, Luthen R, Haussinger D, Sebekova K, Schinzel R, Voelker W, Heidland A (2004) Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis. J Hepatol 41: 913-919
2. Brown TR, Su B, Brown KA, Scgwartz, MA, Tobia AM, Kappler F (2003) Modulation of in vivo 3-deoxyglucosone levels. Biochem Soc Trans 31: 1433-1437
3. Chen F, Wollmer MA, Hoerndli F., Münch G, Kuhla B, Rogaev ET, Tsolaki M, Papassotiropoulos A, Götz J (2004) Role for glyoxalase I in Alzheimer's disease. Proc Natl Acad Sci USA 101: 7687-7692
4. Choei H, Sasaki N, Takeuchi M, Yoshida T, Ukai W, Yamagishi S, Kikuchi S, Saito T (2004) Glyceraldehyde-derived advanced glycation end products in Alzheimer's disease. Acta Neuropathol 108: 189-193
5. Collard F, Wiame E, Bergans N, Fortpied J, Vertommen D, Vanstapel F, Delpierre G, Van Schaftingen E (2004) Fructosamine 3-kinase-related protein and deglycation in human erythrocytes. Biochem J 382: 137143
6. Creighton DJ, Zheng Z-B, Holewinski R, Hamilton DS, Eiseman JL (2003) Glyoxalase I inhibitors in cancer chemotherapy. Biochem Soc Trans 31: 1378-1382
7. Ding Q, Keller JN (2005) Splice variants of the receptor for advanced glycosylation end products (RAGE) in human brain. Neurosci Lett 373: 67-72
8. Dukic-Stefanovic S, Schinzel R, Riederer P, Münch G (2001) AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs? Biogerontology 2: 19-34
9. Gugliucci A, Menini T (2003) The polyamines spermine and spermidine protect proteins from structural and functional damage by AGE precursors: a new role for old molecules. Life Sci 72: 2603-2616
10. Khalifah RG, Baynes JW, Hudson BG (1999) Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 257: 251-258
11. Khula B, Lüth H-J, Haferburg D, Boeck K, Arendt T, Münch G (2005) Methylglyoxal, glyoxal, and their detoxification in Alzheimer's disease. Ann NY Acad Sci 1043: 211-216
12. Ko LW, Ko EC, Nacharaju P, Liu WK, Chang E, Kenessey A, Yen SH (1999) An immunochemical study on tau glycation in paired helical filaments. Brain Res 830: 301-313
13. Kuhla B, Boeck K, Schmidt A, Ogunlade V, Arendt T, Münch G, Lüth H-J (2007) Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains. Neurobiol Aging 28: 29-41
14. Lüth H-J, Münch G, Arendt T (2002) Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Res 953: 135-143
15. Marasinghe GPK, Sander IM, Bennett B, Periyannan G, Yang K-W, Makaroff CA, Crowder M W (2005) Structural studies on a mitochondrial glyoxalase II. J Biol Chem 280: 40668-40675
16. Méndez JD, Leal LI (2004) Inhibition of in vitro pyrraline formation by L-arginine and polyamines. Biomed Pharmacother 58: 598-604
17. Picklo MJ Sr, Olson SJ, Markesbery WR, Montine TJ (2001) Expression and activities of aldo-keto oxidoreductases in Alzheimer disease. J Neuropathol Exp Neurol 60: 686-694
18. Picklo MJ Sr, Montine TY, Amarnath V, Neely MD (2002) Carbonyl toxicology and Alzheimer's disease. Toxicol Appl Pharmacol 184: 187-197
19. Richard JP (1993) Mechanism for the formation of methylglyoxal from triosephosphates. Biochem Soc Trans 21: 549-553
20. Riederer P, Hoyer S (2006) From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain. J Neural Transm 113: 1671-1677
21. Sakamoto H, Mashima T, Sato S, Hashimoto Y, Yamori T, Tsuruo T. (2001) Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I - overexpressing human lung cancer cells. Clin Cancer Res 7: 2513-2518
22. Sasaki N, Takeuchi M, Chowei H, Kikuchi S, Hayashi Y, Nakano N, Ikeda H, Yamagishi S, Kitamoto T, Saito T, Makita Z (2002) Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jacob disease with prion plaques. Neurosci Lett 326: 117-120
23. Sasaki N, Toki S, Chowei H, Saito T, Nakano N, Hayashi Y, Takeuchi M, Makita Z (2001) Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res 888: 256-262
24. Sato T, Iwaki M, Shimogaito N, Wu X, Yamagishi S, Takeuchi M (2006) TAGE (Toxic AGEs) theory in diabetic complications. Curr Mol Med 6: 351-358
25. Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi S, Takeuchi M (2006) Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am J Alzheimers Dis Other Demen 21: 197-208
26. Schmidt AM, Stern DM (2000) RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab 11: 368-375
27. Schmidt AM, Yan SD, Yan SF, Stern DM (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108: 949-955
28. Szwergold BS, Howell S, Beisswengen PJ (2001) Human fructosamine-3- kinase: purification, sequencing, substrate specificity, and evidence of activity in vivo. Diabetes 50: 2139-2147
29. Takahashi M, Pischetsrieder M, Monnier VM (1997) Molecular cloning and expression of amadoriase isoenzyme (fructosyl amine:oxygen oxidoreductase, EC 1.5.3) from Aspergillus fumigatus. J Biol Chem 272: 12505-12507
30. Takeuchi M, Kikuchi S, Sasaki N, Suzuki T, Watai T, Iwaki M, Bucala R, Yamagishi S (2004) Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease. Curr Alzheimer Res 1: 3946
31. Tessier F, Obrenovich M, Monnier VM (1999) Structure and mechanism of formation of human lens fluorophore LM-1. Relationship to vesperlysine A and the advanced Maillard reaction in aging, diabetes, and cataractogenesis. J Biol Chem 274: 20796-20804
32. Thornalley PJ (2003) Glyoxalase I - structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 31: 1343-1348
33. Thornalley P, Wolff S, Crabbe J, Stern A (1984) The autoxidation of glyceraldehyde and other simple monosaccharides under physiological conditions catalysed by buffer ions. Biochim Biophys Acta 797: 276-287
34. Thornalley PJ, Langborg A, Minhas HS (1999) Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344: 109-116
35. Usui T, Shimohira K, Watanabe H, Hayase F (2007) Detection and determination of glyceraldehyde-derived pyridinium-type advanced glycation end product in streptozotocin-induced diabetic rats. Biosci Biotechnol Biochem 71: 442-448
36. Van Herreweghe F, Mao J, Chaplen FW, Grooten J, Gevaert K, Vandekerckhove J, Vancompermolle K (2002) Tumor necrosis factor-induced modulation of glyoxalase I activities through phosphorylation by PKA results in cell death and is accompanied by the formation of a specific methylglyoxal-derived AGE. Proc Natl Acad Sci USA 99: 949-954
37. Voziyan PA, Hudson B (2005) Pyridoxamine. The many virtues of a Maillard reaction inhibitor. Ann NY Acad Sci 1043: 807-816
38. Voziyan PA, Khalifah RG, Thibaudeau C, Yildiz A, Jacob J, Serianni AS, Hudson B (2003) Modification of proteins in vitro by physiological levels of glucose. Pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions. J Biol Chem 278: 46616-46624
39. Wiame E, Delpierre G, Collard F, Van Schaftingen E (2002) Identification of a pathway for the utilization of the Amadori product fructoselysine in Escherichia coli. J Biol Chem 277: 42523-42529
40. Wong A, L™euro;uth H-L, Deuther-Conrad W, Dukic-Stefanovic S, Gasic-Milenkovic J, Arendt T, M™euro;unch G (2001) Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer disease. Brain Res 920: 32-40
41. Xu Y, Chen X (2006) Glyoxalase II, a detoxifying enzyme of glycolysis byproduct methylglyoxal and a target of p63 and p73, is a pro-survival factor of the p53 family. J Biol Chem 281: 26713-26702
42. Yan S-D, Chen X, Schmidt A-M, Brett J, Godman G, Zou Y-S, Scott CW, Caputo C, Frappier T, Smith MA, Perry G, Yen S-H, Stern D (1994) Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 91: 7787-7791
43. Yang BZ, Makita Z, Horii Y, Brunelle S, Cerami A, Sehajpal P, Suthanthiran M, Vlassara H (1991) Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relatioship to macrophage receptor for glucose-modified proteins. J Exp Med 174: 515-524
44. Zyzak DV, Richardson JM, Thorpe SR, Baynes JW (1995) Formation of reactive intermediates from Amadori compounds under physiological conditions. Arch Biochem Biophys 316: 547-554